| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 3,071 | 3,157 | 3,250 | 3,417 | 4,144 | 4,424 | 4,243 | 4,511 | 4,209 | 3,839 | 3,952 | 3,929 | 4,125 | 3,960 | 4,122 | 3,872 | 3,922 | 3,922 | 4,007 | 3,844 | 4,084 | 3,513 | 3,807 | 3,939 | 3,808 | 4,265 | 4,076 | 4,122 | 3,880 | 3,610 | 4,106 | 4,263 | 4,368 | 4,765 | 4,980 | 5,109 | 4,924 | 5,582 | 5,539 | 5,672 | 5,619 | 6,243 |
| Expenses | 2,289 | 2,331 | 2,667 | 2,702 | 2,883 | 3,157 | 3,260 | 3,264 | 3,472 | 3,104 | 3,099 | 3,287 | 4,789 | 3,329 | 3,401 | 3,608 | 3,107 | 3,131 | 3,788 | 3,629 | 3,320 | 3,040 | 3,254 | 3,239 | 3,066 | 3,306 | 5,415 | 3,791 | 3,615 | 3,512 | 3,693 | 3,790 | 3,852 | 3,958 | 4,121 | 4,160 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 |
| EBITDA | 783 | 825 | 583 | 715 | 1,261 | 1,268 | 983 | 1,246 | 737 | 735 | 853 | 642 | -665 | 631 | 721 | 264 | 814 | 791 | 219 | 215 | 763 | 473 | 553 | 700 | 742 | 960 | -1,339 | 331 | 265 | 98 | 414 | 473 | 515 | 807 | 859 | 950 | 960 | 1,223 | 1,207 | 1,261 | 1,273 | 1,702 |
| Operating Profit % | 25 % | 24 % | 16 % | 19 % | 30 % | 27 % | 23 % | 26 % | 17 % | 18 % | 20 % | 16 % | -20 % | 12 % | 13 % | 6 % | 18 % | 18 % | 1 % | 2 % | 12 % | 12 % | 14 % | 17 % | 18 % | 22 % | -35 % | 7 % | 6 % | 3 % | 10 % | 11 % | 11 % | 17 % | 17 % | 18 % | 19 % | 21 % | 21 % | 21 % | 22 % | 26 % |
| Depreciation | 107 | 101 | 116 | 122 | 149 | 203 | 211 | 231 | 267 | 261 | 272 | 280 | 273 | 259 | 266 | 219 | 219 | 250 | 253 | 253 | 214 | 215 | 213 | 244 | 216 | 209 | 919 | 203 | 327 | 193 | 204 | 220 | 264 | 235 | 248 | 257 | 457 | 248 | 257 | 272 | 393 | 299 |
| Interest | 3 | 7 | 24 | 10 | 31 | 35 | 29 | 48 | 41 | 44 | 48 | 54 | 59 | 69 | 74 | 79 | 84 | 84 | 83 | 89 | 107 | 44 | 34 | 31 | 32 | 34 | 34 | 33 | 42 | 43 | 55 | 84 | 93 | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 |
| Profit Before Tax | 697 | 792 | 581 | 781 | 1,170 | 1,156 | 822 | 1,045 | 520 | 494 | 611 | 383 | -941 | 384 | 441 | 93 | 591 | 518 | -54 | -73 | 496 | 273 | 360 | 525 | 518 | 751 | -2,205 | 167 | -85 | 2 | 210 | 246 | 259 | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 |
| Tax | 136 | 224 | 158 | 255 | 417 | 273 | 159 | 410 | 137 | 137 | 154 | 161 | -163 | 181 | 173 | 245 | 294 | 216 | 70 | 767 | 105 | 164 | 147 | 84 | 54 | 202 | -110 | -382 | 427 | 89 | 75 | 89 | 16 | 106 | 134 | 117 | 130 | 188 | 195 | 212 | 114 | 194 |
| Net Profit | 561 | 568 | 422 | 526 | 753 | 883 | 663 | 636 | 384 | 357 | 457 | 222 | -778 | 203 | 269 | -152 | 296 | 303 | -123 | -840 | 391 | 109 | 214 | 441 | 464 | 548 | -2,095 | 549 | -512 | -87 | 135 | 158 | 242 | 453 | 495 | 619 | 368 | 806 | 860 | 859 | 782 | 1,222 |
| EPS in ₹ | 12.17 | 12.65 | 9.34 | 11.67 | 16.63 | 19.57 | 14.69 | 14.04 | 8.42 | 7.93 | 10.07 | 4.91 | -17.33 | 6.40 | 5.88 | -3.37 | 6.55 | 6.69 | -2.72 | -18.56 | 8.64 | 2.36 | 4.66 | 9.67 | 10.15 | 11.96 | -46.22 | 12.01 | -11.40 | -1.96 | 2.85 | 3.38 | 5.19 | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.70 | 18.75 | 16.93 | 26.70 |
Lupin
Lupin
1,961.60
-28.20
(-1.42%)
Market Cap
89,585.40 Cr
EPS
71.95
PE Ratio
24.20
Dividend Yield
0.61 %
Industry
Healthcare52 Week High
2,402.90
52 Week Low
1,795.20
PB Ratio
5.20
Debt to Equity
0.27
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from36 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,641.40 | #1 3,93,826.80 | 34.36 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 46.65 | |
6,132.50 | 1,62,798.60 | 70.57 | 9,712.00 | 18.67 | 2,191 | 26.74 | 37.51 | |
1,564.00 | 1,26,325.50 | 23.42 | 28,409.50 | 7.12 | 5,291 | 9.88 | 62.75 | |
3,623.00 | 1,22,618.80 | 60.70 | 11,539.40 | 6.99 | 1,911 | 19.91 | 57.93 | |
1,260.40 | 1,05,189.30 | #1 18.50 | 33,741.20 | 16.73 | 5,725 | 1.26 | 53.20 | |
2,472.60 | 1,02,051.30 | 53.98 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.22 | |
988.80 | 99,496.40 | 21.34 | 23,511.00 | 18.55 | 4,615 | 2.60 | 57.97 | |
1,961.60 | #8 89,585.40 | #4 24.20 | #5 22,909.50 | #5 13.74 | #5 3,306 | #1 51.64 | 53.80 | |
33,265.00 | 70,685.80 | 48.63 | 6,684.70 | 9.64 | 1,414 | 11.55 | 48.48 | |
5,347.50 | 63,937.40 | 28.11 | 13,458.30 | 3.70 | 2,216 | 21.39 | 68.13 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
13.74 %
Net Income Growth
70.82 %
Cash Flow Change
-17.77 %
ROE
41.95 %
ROCE
20.69 %
EBITDA Margin (Avg.)
22.54 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 13,138 | 22,625 | 26,607 | 26,305 | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 | 29,205 |
| Fixed Assets | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 | 9,719 |
| Current Assets | 7,832 | 9,887 | 11,953 | 12,210 | 13,854 | 15,413 | 13,986 | 12,458 | 12,451 | 13,448 | 16,799 |
| Capital Work in Progress | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 | 517 |
| Investments | 1,656 | 16 | 2,136 | 262 | 2,296 | 2,374 | 2,455 | 900 | 517 | 1,075 | 1,146 |
| Other Assets | 6,538 | 11,189 | 11,305 | 13,084 | 12,928 | 13,732 | 12,209 | 12,393 | 12,846 | 13,272 | 17,823 |
| Total Liabilities | 13,138 | 22,625 | 26,607 | 26,305 | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 | 29,205 |
| Current Liabilities | 3,729 | 5,061 | 6,121 | 5,096 | 6,130 | 9,225 | 8,436 | 8,498 | 9,265 | 8,502 | 8,961 |
| Non Current Liabilities | 510 | 6,368 | 6,955 | 7,593 | 8,030 | 3,178 | 1,316 | 1,101 | 1,148 | 1,122 | 2,949 |
| Total Equity | 8,898 | 11,196 | 13,532 | 13,617 | 13,789 | 12,581 | 13,858 | 12,222 | 12,543 | 14,374 | 17,294 |
| Reserve & Surplus | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 | 17,112 |
| Share Capital | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 1,502 | -1,315 | 2,019 | 729 | -872 | 1,685 | -1,303 | 87 | 273 | -248 | 560 |
| Investing Activities | -1,034 | -6,769 | -2,527 | 470 | -3,283 | 1,107 | -1,240 | 1,292 | -1,287 | -1,712 | -4,172 |
| Operating Activities | 2,733 | -382 | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | 367 | 1,897 | 3,648 | 3,000 |
| Financing Activities | -197 | 5,836 | 433 | -1,492 | 744 | -891 | -1,885 | -1,572 | -337 | -2,184 | 1,732 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 46.86 % | 46.84 % | 46.83 % | 46.81 % | 46.78 % | 47.10 % | 47.11 % | 47.10 % | 47.08 % | 47.07 % | 47.05 % | 47.04 % | 47.01 % | 46.98 % | 46.96 % | 46.95 % | 46.92 % | 46.90 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 16.11 % | 18.28 % | 19.32 % | 21.50 % | 22.04 % | 21.46 % | 21.25 % |
| DIIs | 22.08 % | 21.68 % | 24.38 % | 24.76 % | 26.84 % | 26.82 % | 27.54 % | 29.38 % | 29.21 % | 28.98 % | 29.42 % | 29.73 % | 27.76 % | 26.78 % | 25.09 % | 24.74 % | 25.41 % | 25.56 % |
| Government | 0.29 % | 0.28 % | 0.28 % | 0.28 % | 0.29 % | 0.29 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 10.02 % | 9.91 % | 10.18 % | 9.99 % | 8.53 % | 8.59 % | 8.41 % | 8.06 % | 7.86 % | 7.06 % | 6.24 % | 5.87 % | 5.70 % | 5.65 % | 5.29 % | 5.17 % | 5.10 % | 5.23 % |
| Others | 20.75 % | 21.29 % | 18.34 % | 18.16 % | 17.57 % | 17.19 % | 16.94 % | 15.45 % | 15.85 % | 16.89 % | 17.27 % | 1.23 % | 1.23 % | 1.26 % | 1.15 % | 1.10 % | 1.10 % | 1.05 % |
| No of Share Holders | 0 | 2,93,782 | 3,02,292 | 3,61,288 | 3,61,862 | 3,78,547 | 3,82,828 | 3,78,011 | 3,60,677 | 3,22,678 | 2,89,074 | 2,81,542 | 2,80,248 | 2,88,537 | 2,79,280 | 2,81,988 | 2,83,210 | 2,86,604 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 7.5 | 5 | 5 | 6 | 6.5 | 4 | 4 | 8 | 12 |
| Dividend Yield (%) | 0.00 | 1.02 | 0.68 | 0.85 | 0.59 | 0.87 | 0.61 | 0.25 | 0.39 | 0.61 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 11 Aug 2025 |  Annual General Meeting | NA | 11 Aug 2025 | 1,894.70 | 1,918.00 |
| 05 Aug 2025 |  Quarterly Result Announcement | NA | 05 Aug 2025 | 1,930.85 | 1,882.20 |
| 25 Jul 2025 |  Dividend | ₹ 12.00 /share | 25 Jul 2025 | 2,063.00 | 1,943.40 |
| 14 May 2025 | Quarterly Result Announcement | NA | 14 May 2025 | 2,107.70 | 2,063.00 |
| 11 Feb 2025 | Quarterly Result Announcement | NA | 11 Feb 2025 | 2,134.25 | 2,169.40 |
| 07 Nov 2024 | Quarterly Result Announcement | NA | 07 Nov 2024 | 2,151.95 | 2,166.05 |
| 02 Aug 2024 | Annual General Meeting | NA | 02 Aug 2024 | 1,778.90 | 1,953.55 |
| 16 Jul 2024 | Dividend | ₹ 8.00 /share | 16 Jul 2024 | 1,655.25 | 1,832.10 |
| 14 Jul 2023 | Dividend | ₹ 4.00 /share | 14 Jul 2023 | 732.25 | 930.75 |
| 15 Jul 2022 | Dividend | ₹ 4.00 /share | 14 Jul 2022 | 683.30 | 643.20 |
| 28 Jul 2021 | Dividend | ₹ 6.50 /share | 27 Jul 2021 | 1,212.25 | 1,111.60 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Change in Directorate6 days ago
6 days agoShareholder Meeting / Postal Ballot-Scrutinizers Report6 days ago
6 days agoShareholder Meeting / Postal Ballot-Outcome of AGM6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 05, 2025
Aug 05, 2025Board Meeting Outcome for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025.Aug 05, 2025
Aug 05, 2025Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025.Aug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 05, 2025
Aug 05, 2025Rumour verification - Regulation 30(11)Aug 01, 2025
Aug 01, 2025Clarification sought from Lupin LtdAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 25, 2025
Jul 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 24, 2025
Jul 24, 2025Reg. 34 (1) Annual Report.Jul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 21, 2025
Jul 21, 2025Board Meeting Intimation for Considering And Taking On Record Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025.Jul 21, 2025
Jul 21, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 19, 2025
Jul 19, 2025Reg. 34 (1) Annual Report.Jul 19, 2025
Jul 19, 2025Notice For Forty-Third Annual General Meeting Of The Company And Integrated Report For FY 2024-25.Jul 19, 2025
Jul 19, 2025Inspection Of U.S. FDA At The Companys Pithampur Unit-3 Manufacturing Facility.Jul 17, 2025
Jul 17, 2025Inspection Of U.S. FDA At The Companys Pithampur Unit-2 Manufacturing Facility.Jul 17, 2025
Jul 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 17, 2025
Jul 17, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 15, 2025
Jul 15, 2025Intimation Of Record Date For Payment Of Final Dividend If Declared.Jul 14, 2025
Jul 14, 2025Intimation Of The Forty-Third Annual General Meeting Of The Company And Record Date For Payment Of Dividend.Jul 14, 2025
Jul 14, 2025ESG Rating By NSE Sustainability Ratings & Analytics Limited.Jul 10, 2025
Jul 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 09, 2025
Jul 09, 2025License And Supply AgreementJul 08, 2025
Jul 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 07, 2025
Jul 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 04, 2025
Jul 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 01, 2025
Jul 01, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 01, 2025
Jul 01, 2025Execution Of Business Transfer Agreement For Transfer Of Its API R&D Division Situated At Pune To Lupin Manufacturing Solutions Limited A Wholly Owned Subsidiary Of The Company On A Slump Sale Basis.Jun 30, 2025
Jun 30, 2025Execution Of Business Transfer Agreement For Transfer Of Its Over-The-Counter Consumer Healthcare Business To LUPINLIFE Consumer Healthcare Limited A Wholly Owned Subsidiary Of The Company On A Slump Sale Basis.Jun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 25, 2025
Jun 25, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 24, 2025
Jun 24, 2025Intimation Regarding Grant Of Stock Options Under Lupin Employees Stock Option PlansJun 20, 2025
Jun 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 16, 2025
Jun 16, 2025Technical Indicators
RSI(14)
Neutral 53.80
ATR(14)
Volatile 47.58
STOCH(9,6)
Neutral 72.35
STOCH RSI(14)
Overbought 84.15
MACD(12,26)
Bullish 7.78
ADX(14)
Weak Trend 14.67
UO(9)
Bearish 51.74
ROC(12)
Downtrend And Accelerating -1.16
WillR(14)
Neutral -27.86
Mutual Fund Holdings
HDFC Large Cap Fund Direct-Growth 
HSBC Midcap Fund Direct-Growth 
SBI Arbitrage Opportunities Fund Direct-Growth 
Axis Midcap Direct Plan-Growth 
Nippon India Multi Cap Fund Direct-Growth 
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth 
Kotak Arbitrage Fund Direct-Growth 
Franklin India Mid Cap Fund Direct-Growth 
Tata Arbitrage Fund Direct - Growth 
Invesco India Contra Fund Direct-Growth 
Mirae Asset Midcap Fund Direct - Growth 
HDFC Innovation Fund Direct-Growth 
Aditya Birla Sun Life Arbitrage Fund Direct-Growth 
Bandhan Flexi Cap Fund Direct-Growth About Lupin
Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The company has expanded through acquisitions and partnerships, entering markets in Japan, Germany, Australia, South Africa, and the Philippines. Lupin has manufacturing facilities in various locations and has received FDA approvals for multiple generic drugs. The company has also launched innovative products and entered strategic alliances with other pharmaceutical companies for drug development and marketing.
Website
Chairperson NameM D Gupta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
